Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $232M | $240M | $277M | $409M | $444M | $484M | $510M | $592M | $661M | $727M |
| Revenue growth | — | 3.6% | 15.2% | 47.7% | 8.7% | 9.0% | 5.2% | 16.1% | 11.6% | 10.1% |
| Gross profit | $98.1M | $102M | $127M | $197M | $186M | $187M | $188M | $245M | $290M | $314M |
| Gross margin | 42.3% | 42.4% | 46.0% | 48.1% | 41.8% | 38.6% | 36.9% | 41.3% | 43.9% | 43.2% |
| Operating income | $2.15M | $2.90M | $10.0M | $13.0M | -$14.0M | -$119M | -$158M | -$108M | -$92.1M | -$116M |
| Operating margin | 0.9% | 1.2% | 3.6% | 3.2% | -3.1% | -24.5% | -30.9% | -18.2% | -13.9% | -15.9% |
| Net income | -$6.14M | -$396K | $2.64M | $8.01M | $4.17M | -$8.35M | -$144M | -$88.0M | -$78.7M | -$108M |
| Net margin | -2.6% | -0.2% | 1.0% | 2.0% | 0.9% | -1.7% | -28.3% | -14.9% | -11.9% | -14.9% |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $21.5M | $18.0M | $44.8M | $23.4M | $1.46M | -$26.7M | -$66.0M | -$1.95M | $7.02M | $5.23M |
| Capital expenditures | $7.54M | $13.7M | $14.3M | $20.0M | $29.1M | $64.1M | $30.9M | $28.8M | $41.1M | $27.0M |
| Free cash flow | $13.9M | $4.35M | $30.5M | $3.34M | -$27.6M | -$90.9M | -$96.9M | -$30.7M | -$34.0M | -$21.8M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $12.5M | $12.8M | $9.81M | $173M | $229M | $317M | $263M | $342M | $367M | $160M |
| Total assets | $337M | $344M | $505M | $710M | $988M | $1.87B | $1.74B | $1.68B | $1.64B | $1.36B |
| Total liabilities | $151M | $140M | $185M | $202M | $294M | $762M | $742M | $740M | $736M | $523M |
| Long-term debt | $91.9M | $91.1M | $92.9M | — | — | — | — | $538M | $340M | $342M |
| Shareholders' equity | $162M | $172M | $320M | $507M | $694M | $1.11B | $998M | $942M | $902M | $837M |
| Retained earnings | -$52.5M | -$58.4M | -$19.4M | -$11.4M | -$7.18M | -$14.8M | -$159M | -$247M | -$326M | -$434M |
| Shares (wtd avg diluted) | 77.5M | 79.4M | 91.6M | 104M | 112M | 120M | 124M | 126M | 127M | 128M |
Every figure is extracted from NEOGENOMICS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.